Value-Based Contracting Services

Multiple stakeholders and the data hurdle

Value-based contracts (VBCs) and value-based care are promising ways to accelerate the shift from volume to value in health care. These arrangements between life sciences manufacturers (pharmaceuticals and medical technology) and payers and providers will play a critical role in enabling appropriate access to new innovations and tools for value-based care. They can improve patients’ health, by sharing risk across stakeholders and helping to control costs. Drug pricing will likely be a top priority for Congress in 2019, increasing the need for companies to demonstrate value.

While the number of publicly announced value-based contracts between life sciences companies and payers has increased over the past few years, there continues to be barriers preventing wider spread adoption. According to Deloitte’s 2018 real-world evidence (RWE) benchmarking survey, participants ranked challenges with collecting, linking, and analyzing data as the biggest hurdle, along with gaining stakeholder alignment and assigning value-based care to benefit.

How Deloitte can help with value-based contracts enablement

The right team. Demonstrated experience.

Deloitte has the breadth and depth of capabilities to help the health care and life sciences sector overcome these barriers. Our Value-based Care practice, repeatedly acknowledged by KLAS as the leader in our field, acts as a trusted intermediary for multi-stakeholder contracts. We take a healthy mix of cross-functional perspectives, from actuaries to data scientists, from industry consultants to technologists, to help facilitate the necessary shifts from volume to value-based care. Our approach outlined below entails value-based contracting strategy as well as operationalizing the arrangements in an end-to-end lifecycle.

Get in touch

If you want more details about how Deloitte can help strategize, design, execute, and adjudicate VBCs while managing health care reimbursement models, we should talk.